Guest guest Posted March 9, 2011 Report Share Posted March 9, 2011 New Data on Telaprevir and VX-222 for the Treatment of Hepatitis From the PharmaLive.com News Archive - Mar. 07, 2011 Vertex Pharmaceuticals said 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.